UniQure's HD therapy faces unethical FDA delay
The guest argued the FDA's demand for a placebo-controlled trial for UniQure's Huntington's disease gene therapy is unethical, as it would deny treatment to patients in a specific functional cohort who would then be permanently ineligible.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.